Humate-P is approved by the Food and Drug Administration (FDA) to control and prevent bleeding in adults with hemophilia A. Humate-P is also used to treat bleeding episodes and for perioperative (before, during, and after surgery) care in adults and children with von Willebrand disease. The technical name of Humate-P is Antihemophilic factor/von Willebrand factor complex (human).
Humate-P is a clotting factor. Clotting factors work by supplying proteins missing in people with hemophilia.
How do I take it?
Prescribing information states that Humate-P is given as an intravenous injection.
Humate-P comes as a powder that must be reconstituted before injection.
The FDA-approved label for Humate-P lists common side effects including itching, rash, and redness or irritation at injection sites.
Rare but serious side effects listed for Humate-P include thromboembolic events, the development of inhibitors, and life-threatening hypersensitivity reactions.
For more details about this treatment, visit:
Treatment of Hemophilia – Hemophilia Federation of America